Detection of anti-TNFα activity in canine hyperimmune serum using a TNFα inhibition assay

Veterinary Clinical Pathology

Volumn 39, Issue 1, 2010, Pages 46-52

  Kotiw, Michael ^a   Morgan, Michael ^b   Taylor, Stephen M ^b   Shiels, Ian A ^b  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Dog; Escherichia coli J5; Hyperimmune serum; L929 cell assay; TNF inhibition

Indexed keywords

CANIS FAMILIARIS; ESCHERICHIA COLI; RATTUS;

ANTISERUM; BACTERIAL VACCINE; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOASSAY; CELL LINE; DOG; DRUG ANTAGONISM; ESCHERICHIA COLI; FLUOROIMMUNOASSAY; IMMUNOLOGY; MALE; METHODOLOGY; MOUSE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BACTERIAL VACCINES; BIOLOGICAL ASSAY; CELL LINE; DOGS; ESCHERICHIA COLI; FLUOROIMMUNOASSAY; IMMUNE SERA; IMMUNOGLOBULIN G; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954375261     PISSN: 02756382     EISSN: 1939165X     Source Type: Journal    
DOI: 10.1111/j.1939-165X.2009.00166.x     Document Type: Article

References (38)

1. Baggio V, Ott F, Fischer RW. Production of antibodies to canine IL-1β and canine TNF to assess the role of proinflammatory cytokines. Vet Immunol Immunopathol 2005, 107:27-39.
2. Tartaglia LA, Goeddel DV. Tumor necrosis factor receptor signalling: a dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J Biol Chem 1992, 267:4304-4307.
3. Aderka D, Englemann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175:323-329.
4. Mohler KM, Torrance DS, Smith CA. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxaemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151:1548-1561.
5. Ellerin T, Rubin IH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 2003, 48:3013-3022.
6. Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, Feng Q. In vivo TNF-α inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 2004, 287:H1813-H1820.
7. Buscaglia JM, Simons BW, Prosser BJ. Etanercept, a TNF-alpha binding agent, is ineffective in the prevention of post-ERCP pancreatitis in canines. J Pancreas 2008, 9:456-467.
8. Gu Q, Yang XP, Bonde P, DiPaula A, Fox-Talbot K, Becker LC. Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol 2006, 48:320-328.
9. Fujita Y, Hara Y, Nezu Y, Schulz KS, Tagawa M. Proinflammatory cytokine activities, matrix metalloproteinase-activity, and sulfated glycosaminoglycan content in synovial fluid of dogs with naturally acquired cranial cruciate ligament rupture. Vet Surg 2006, 35:369-376.
10. Sakaue Y, Nezu Y, Yanagisawa S. Effects of continuous low-dose infusion of lipopolysaccharide on expression of E-selectin and intercellular adhesion molecule-1 messenger RNA and neutrophil accumulation in specific organs in dogs. Am J Vet Res 2005, 66:1259-1266.
11. Kobayashi S, Baba H, Uchida K. Effect of mechanical compression on the lumbar nerve root: localization and changes of intraradicular inflammatory cytokines, nitric oxide, and cyclooxygenase. Spine 2005, 30:1699-1705.
12. Sentürk S. Evaluation of the anti-endotoxic effects of polymyxin-E (colistin) in dogs with naturally occurred endotoxic shock. J Vet Pharmacol Ther 2003, 28:57-63.
13. Beutler B, Milsark IW, Cerami A. Passive immunization against cachectin/tumor necrosis factor (TNF) protects mice from the lethal effect of endotoxin. Science 1985, 229:869-871.
14. Nophar Y, Kemper O, Brakebusch C. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both cell surface and soluble form of the receptor. Eur Mol Biol Org J 1990, 9:3269-3278.
15. Waetzig GH, Rosensteil P, Arlt A. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signalling and autocrine transforming growth factor-β1. FASEB J 2005, 19:91-93.
16. Inanc N, Direskeneli H. Serious infections under treatment with TNFα antagonists compared to traditional DMRADS in patients with rheumatoid arthritis. Rheumatol Internat 2006, 27:67-71.
17. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002, 20:152-157.
18. Kotiw M, Shiels IA, Wilson RP, Reeve-Johnson L. In vitro effect of hypeimmune sera on TNFα activity [abstract]. J Vet Pharmacol Ther 2006, 29(8 (Suppl 1)):C12.
19. Kotiw M, Morgan M, Lopez J, Taylor SM, Shiels IA. In vitro and in vivo determination of antiTNFα activity in canine plasma from donors subject to preconditioning with endotoxin [abstract]. Crit Care 2007, 11((Suppl 4)):P23.
20. Gonzalez RN, Cullor JS, Jasper DE, Farver TB, Bushnell RB, Oliver MN. Prevention of clinical coliform mastitis in dairy cows by a mutant Escherichia coli vaccine. Can J Vet Res 1989, 53:301-305.
21. Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989, 264:11966-11973.
22. Nagase M, Baker DG, Schumacher HR. Prolonged inflammatory reactions induced by artificial ceramics in the rat air pouch model. J Rheumatol 1988, 15:1334-1338.
23. Gao Y, Hansson M, Calafat J, Tapper H, Olsson I. Sorting soluble tumor necrosis (TNF) receptor for storage and regulated secretion in hematopoietic cells. J Leukoc Biol 2004, 76:876-885.
24. Ruaux CG, Pennington HL, Worrall S, Atwell RB. Tumor necrosis factor-α at presentation in 60 cases of spontaneous canine acute pancreatitis. Vet Immunol Immunopathol 1999, 72:369-376.
25. Khono T, Brewer MT, Baker SL. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 1990, 87:8331-8335.
26. Hegemann N, Wondimu A, Kohn B, Brunnberg L, Schmidt MF. Cytokine profiles in canine immune-mediated polyarthritis and osteoarthritis. Vet Comp Orthop Traumatol 2005, 18:67-72.
27. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998, 95:570-575.
28. Wang M, Meng X, Tsai B. Preconditioning up-regulates the soluble TNF receptor I response to endotoxin. J Surg Res 2004, 121:20-24.
29. Negi VS, Elluru A, Siberil S. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007, 27:233-245.
30. Holzheimer RG. Immunoglobulins for prophylaxis and treatment of sepsis: new experience with a natural immunomodulatory compound. Sepsis 1999, 3:193-196.
31. Nys M, Damas J, Damas P, Laub R, Cloes JM, Lamy M. Study of the protective effects of hyperimmune immunoglobulins G and M against endotoxin in mice and rats. Med Microbiol Immunol 1999, 188:55-64.
32. Gianotti L, Braga M, Vaiani R, Almondo F, Di Carlo V. Experimental gut-derived endotoxaemia and bacteraemia are reduced by systemic administration of monoclonal anti-LPS antibodies. Burns 1996, 22:120-124.
33. Cometta A, Baumgartner JD, Glauser MP. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol 1994, 1((Suppl)):69-72.
34. Barclay GR. Endotoxin-core antibodies: time for a reappraisal? Intensive Care Med 1999, 25:427-429.
35. Hamilton-Davies C, Barclay GR, Murphy WG, Machin SJ, Webb AR. Passive immunization with IgG endotoxin core antibody hyperimmune fresh frozen plasma. Vox Sang 1996, 71:165-169.
36. Bennett-Guerrero E, Ayuso L, Hamilton-Davies C. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. J Am Med Assoc 1997, 277:646-650.
37. Calvano SE, van der Poll T, Coyle SM, Barie PS, Moldawer LL, Lowry SF. Monocyte tumour necrosis factor receptor levels as a predictor of risk in human sepsis. Arch Surg 1996, 131:434-437.
38. Evans TJ, Moyes D, Carpenter A. Protective effect of 55- but not 75-kDa soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994, 180:2173-2179.